![Juliette Audet](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Juliette Audet
Corporate Officer/Principal at FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Juliette Audet active positions
Companies | Position | Start | End |
---|---|---|---|
FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 2024-03-31 | - |
Director/Board Member | 2022-10-31 | 2024-03-31 | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Analyst | 2019-09-30 | - |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Director/Board Member | 2019-12-31 | - |
Mestag Therapeutics Ltd.
![]() Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - | - |
NewAmsterdam Pharma BV
![]() NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Director/Board Member | - | - |
Career history of Juliette Audet
Former positions of Juliette Audet
Companies | Position | Start | End |
---|---|---|---|
Novartis Venture Funds (USA)
![]() Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Private Equity Investor | 2017-12-31 | 2019-07-29 |
ANNEXON, INC. | Director/Board Member | - | - |
NOVARTIS AG | Corporate Officer/Principal | - | - |
TSCAN THERAPEUTICS, INC. | Director/Board Member | - | - |
Training of Juliette Audet
École Polytechnique Fédérale de Lausanne | Graduate Degree |
Harvard Business School | Masters Business Admin |
Statistics
International
United States | 5 |
Netherlands | 5 |
Switzerland | 3 |
Operational
Director/Board Member | 6 |
Corporate Officer/Principal | 2 |
Private Equity Investor | 1 |
Sectoral
Health Technology | 7 |
Finance | 4 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
TSCAN THERAPEUTICS, INC. | Health Technology |
NOVARTIS AG | Health Technology |
ANNEXON, INC. | Health Technology |
Private companies | 5 |
---|---|
Novartis Venture Funds (USA)
![]() Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Finance |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
Mestag Therapeutics Ltd.
![]() Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Finance |
NewAmsterdam Pharma BV
![]() NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Juliette Audet
- Experience